Built on NuGEN's Proprietary Ribo-SPIA(TM) Technology to Achieve Linear Amplification of mRNA
SAN CARLOS, Calif--(BUSINESS WIRE via COLLEGIATE PRESSWIRE)--Sep 7, 2005--NuGEN Technologies Inc., a privately held company that develops and commercializes the new standard in nucleic acid amplification and labeling systems, today announced the launch of the WT-Ovation(TM) RNA Amplification System. The latest product in NuGEN`s Ovation(TM) family, WT-Ovation(TM), utilizes an amplification approach that is based on NuGEN`s proprietary Ribo-SPIA(TM) technology, achieving an average of 1,500-fold linear amplification of mRNA. Following a 3.5 hour amplification process, micrograms of single-stranded cDNA product are generated from as little as 5 ng of total RNA, delivering a cDNA product that is ready for real-time quantitative PCR. This enables researchers to conduct gene studies even when only small amounts of RNA are obtainable.
''Current RNA amplification systems are limited because they rely on the 3` end of the RNA to initiate amplification. These 3`-biased methods only amplify mRNA with intact Poly-A,'' said Elizabeth Hutt, vice president of commercial operations at NuGEN. ''WT-Ovation provides a revolutionary approach to RNA amplification. Whole Transcript Amplification effectively initiates the process from anywhere along the mRNA without the need for a Poly-A tail. For the first time, researchers can interrogate the full length of the transcripts regardless of the presence or absence of a Poly-A tail. For example, they can now effectively study splice variants, examine archived or degraded samples, investigate prokaryotic samples, and at the same time bank or archive amplification products of precious samples.''
The WT-Ovation(TM) product is powered by the company`s proprietary Ribo-SPIA(TM) technology, a patented linear amplification method that generates sensitive and high fidelity results. Pre-amplification produces cDNA in proportion to the amount of mRNA species in a sample, maintaining representation, and subsequently enhancing the sensitivity of QPCR analyses. As with other Ovation(TM) products, WT-Ovation(TM) requires the same small input and delivers unparalleled yield, fidelity and representation in one day.
''WT-Ovation is a distinctly different amplification approach that delivers superior speed, performance and convenience to whole-transcript analysis,'' said Elizabeth Davila, CEO of NuGEN. ''Studying messenger RNA populations across the entire transcriptome is now a reality, and WT-Ovation provides an automation-friendly solution to researchers who have high throughput volumes.''
For pricing and availability information for the WT-Ovation(TM) RNA Amplification System, please contact NuGEN Technologies at 888-654-6544 or [email protected].
About NuGEN Technologies Inc.
NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company`s technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN`s proprietary SPIA(TM) and Ribo-SPIA(TM) amplification and labeling system for DNA- and RNA-based applications form the foundation for a wide range of methods and products used by life
scientists. The Ovation(TM) amplification and labeling system, the company`s first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.
NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies Inc. All other marks are the property of their respective owners.
This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company`s technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company`s current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
|
